The Calcium Channel Blocker by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Calcium Channel Blocker Market:
https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

According to The Business Research Company’s Calcium Channel Blocker, The calcium channel blocker market size has grown strongly in recent years. It will grow from $14.72 billion in 2023 to $15.75 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increased incidence of cardiovascular diseases, aging population, advancements in medical research, changing lifestyles, increased awareness.

The calcium channel blocker market size is expected to see strong growth in the next few years. It will grow to $20.64 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to rising global burden of cardiovascular diseases, personalized medicine trends, increased access to healthcare, expansion of indications, regulatory approvals and market expansions. Major trends in the forecast period include market growth, technological advancements, regulatory landscape, competitive analysis, patient preferences and awareness.

The increasing prevalence rate of cardiovascular diseases is expected to boost the growth of the calcium channel blocker market going forward. Cardiovascular disease refers to a type of condition that affects the heart or blood vessels. Calcium channel blockers (CCBs) are used to lower the risk of heart failure and stroke. Hence, the increasing prevalence rate of cardiovascular diseases will result in a rise in demand for the calcium channel blockers. For instance, in August 2022, according to a report published by the American College of Cardiology, a US-based non-profit medical association, In the United States, it is anticipated that all four cardiovascular risk factors will increase between 2025 and 2060. The largest percentage rise is expected in diabetes, with a 39.3% increase to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also observed that the most substantial projected increases in cardiovascular disease rates were for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Therefore, the increasing prevalence rate of cardiovascular diseases is driving the growth of the calcium channel blocker market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=9428&type=smp

The calcium channel blocker market covered in this report is segmented –
1) By Drug Class: Dihydropyridine, Benzothizepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Product innovation is the key trend gaining popularity in the calcium channel blocker market. Major companies operating in the calcium channel blockers market are focusing on developing innovative products to sustain their market position. For instance, in June 2022, CMP Pharma, a US-based pharmaceutical manufacturing company, launched Norliqva, the first and only oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker. The unique feature of Norliqva is that it is an amlodipine liquid solution used to treat hypertension in people 6 years of age and older. Norliqva prevents the difficulties and irregularities of crushing or synthesizing amlodipine tablets and guarantees uniform dosing and bioequivalence. Norliqva is meant for a subset of patients who require amlodipine but have swallowing issues or are unable to swallow.

The calcium channel blocker market report table of contents includes:

1. Executive Summary

2. Calcium Channel Blocker Market Characteristics

3. Calcium Channel Blocker Market Trends And Strategies

4. Calcium Channel Blocker Market - Macro Economic Scenario

5. Global Calcium Channel Blocker Market Size and Growth

....

31. Global Calcium Channel Blocker Market Competitive Benchmarking

32. Global Calcium Channel Blocker Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Calcium Channel Blocker Market

34. Calcium Channel Blocker Market Future Outlook and Potential Analysis

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model